PTGFRN and prostate cancer: In addition, according to the FPRP results, we confirmed that the MnSOD Val16Ala polymorphism was associated with cancer risk for prostate cancer (heterozygous: FPRP = 0.020 and dominant: FPRP = 0.006), Caucasians (heterozygous: FPRP = 0.008 and dominant: FPRP = 0.045), population-based studies (homozygous: FPRP = 0.136, heterozygous: FPRP = 0.032 and dominant: FPRP = 0.119), hospital-based studies (allele comparison: FPRP = 0.082), low-quality studies (allele comparison: FPRP = 0.138), and high-quality studies (heterozygous: FPRP = 0.119).